CancerCare® to Host Festival of Hope Gala on May 11, 2022

CancerCare, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, is thrilled to announce the 34th Festival of Hope Gala will be held in-person on Wednesday, May 11, 2022, at the Park Savoy, in Florham Park, NJ.

This annual event is an important opportunity to honor individuals and organizations that have made substantial contributions to improving the lives of people affected by cancer through their partnerships with CancerCare. “This year, our Festival of Hope Gala feels somehow even more true to its name,” shared Kathy Nugent, LCSW, Senior Director of Regional Programs. “We are hopeful for the coming year and look forward to celebrating CancerCare’s supporters in-person once again. We are extremely thankful for the generous and continued support from our community over the last few years. It is because of our supporters’ generosity that we continue to provide free, direct services to those who are affected by a cancer diagnosis.”

This year, CancerCare is excited to announce that the recipient of the 2022 Corporate Achievement Award is UroGen, a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.

Accepting the Corporate Achievement Award on behalf of UroGen, Liz Barrett, President and Chief Executive Officer, shared “I am honored to accept this award on behalf of UroGen and our dedicated team who work tirelessly to make a meaningful difference in the lives of the patients we serve. We continue to focus on fundamentally changing the treatment paradigm for some of the most underserved cancers aspiring to deliver better medicines to patients in ways that have never been done before because patients deserve better.”

CancerCare would like to thank all sponsors for this event, including Premier Sponsor UroGen Pharma and Patron Sponsor Eisai. Contributor Sponsors include AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Janssen Oncology, Doron Krakow and the Krakow family, the Morrone family and Pfizer.

Click here to learn more about the 2022 Festival of Hope Gala.

About CancerCare®
Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Our comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by master’s-prepared oncology social workers and world-leading cancer experts. To learn more, visit our website or call 800-813-HOPE (4673).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Back to Press Releases

Back to Top
Terms of Use and Privacy Policy

By using our website, you agree to our recently updated Privacy Policy . Here you can read more about our use of cookies which help us make continuous improvements to our website. Privacy Policy.